Amgen (AMGN) Net Margin (2009 - 2026)
Amgen (AMGN) recorded quarterly Net Margin of 21.11% in Q1 2026, up 56.22% quarter-over-quarter from 13.51% in Q4 2025, and down 12.0% on a YoY basis from 23.99% in Q1 2025.
Amgen (AMGN) Net Margin (2009 - 2026) Analysis & Trends
Amgen's Net Margin history runs 18 years deep, the most recent figure standing at 21.11% for Q1 2026.
- In Q1 2026, Net Margin fell 12.0% year-over-year to 21.11%; the TTM figure through Mar 2026 stood at 20.96% (up 357.0% YoY), while the FY2025 annual figure was 20.98%, up 875.0% from the prior year.
- Net Margin was 21.11% for Q1 2026 at Amgen, up from 13.51% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 352.07% in Q4 2022 to a low of 1.52% in Q1 2024.
- Historically, Net Margin has averaged 40.07% across 5 years, with a median of 21.11% in 2026.
- The sharpest annual moves came in 2022 and 2023: Net Margin soared 32433 bps in 2022, then plunged 34271 bps in 2023.
- A 5-year view of Net Margin shows it stood at 352.07% in 2022, then sank by 97 bps to 9.36% in 2023, then dropped by 26 bps to 6.9% in 2024, then jumped by 96 bps to 13.51% in 2025, then surged by 56 bps to 21.11% in 2026.
- The last three Net Margin figures came in at 21.11% (Q1 2026), 13.51% (Q4 2025), and 33.65% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 22.77% |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 37.36% |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 21.76% |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 4.65% |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -25.84% |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 21.11% |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 29.04% |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -0.56% |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 23.32% |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.11% |
| Dec 31, 2025 | 13.51% |
| Sep 30, 2025 | 33.65% |
| Jun 30, 2025 | 15.60% |
| Mar 31, 2025 | 21.23% |
| Dec 31, 2024 | 6.90% |
| Sep 30, 2024 | 33.28% |
| Jun 30, 2024 | 8.89% |
| Mar 31, 2024 | -1.52% |
| Dec 31, 2023 | 9.36% |
| Sep 30, 2023 | 25.06% |
| Jun 30, 2023 | 19.74% |
| Mar 31, 2023 | 46.54% |
| Dec 31, 2022 | 352.07% |
| Sep 30, 2022 | 32.22% |
| Jun 30, 2022 | 19.97% |
| Mar 31, 2022 | 23.66% |
| Dec 31, 2021 | 27.74% |
| Sep 30, 2021 | 28.09% |
| Jun 30, 2021 | 7.11% |